CD33 and breast cancer: In a cohort of 85 BC patients undergoing a cystectomy, eMDSCs (CD33+HLA-DR-CD15-CD14-) were the predominant subtype of MDSCs in 57% of patients and PMN-MDSCs (CD33+HLA-DR-CD15+CD14-) in 43%.